LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ·NASDAQ

$7.01

-0.14%
HealthcareBiotechnology

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

At a Glance

Live Snapshot
Market Cap$219.79M
EPS-2.8500
P/E Ratio-2.46
Earnings Date07/29/2026

lenz

Total Non-Current Liabilities

Last Annual Value

350.00K

3-Year CAGR

-82%

5-Year CAGR

2%

10-Year CAGR

%

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Competitors Analysis of Total Non-Current Liabilities

LENZ · NASDAQ
CompanyTotal Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
350.00K
-86.6%-59.3%N/A 
SVRA logo
Savara Inc.
NASDAQ:SVRA
29.91M
4.0%11.4%-6.9%
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
1.45M
-14.8%-36.9%13.8%
174.25M
1576.2%15.6%N/A
12.04M
-8.9%-12.8%-15.2%
233.13M
83.0%33.9%N/A
352.95M
-16.7%-22.7%N/A
5.34M
-5.2%31.7%N/A
184.42M
248.5%111.9%N/A
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc. Fair Value Envelope

LENZ · NASDAQ

Our analysis suggests that LENZ has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $7.01, this represents a potential HIDDEN relative to our calculated worth for LENZ Therapeutics, Inc..

Intrinsic Value
Current Price: $7.01